Assignee
ALMIRALL SA
ES·41 granted patents·29 pending applications·179 citations·filing 2005–2025
Top patents by PatentIndex Score
70 records- 0196US7750023B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2008·Granted Jul 6, 2010·27 cites·13 claims
- 0295US7897617B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2010·Granted Mar 1, 2011·21 cites·13 claims
- 0394US9333195B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2015·Granted May 10, 2016·8 cites·14 claims
- 0494US8802699B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2013·Granted Aug 12, 2014·12 cites·10 claims
- 0593US9056100B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2014·Granted Jun 16, 2015·9 cites·14 claims
- 0691US9687478B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2016·Granted Jun 27, 2017·5 cites·14 claims
- 0789US7964615B2Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptorALMIRALL SA·Filed 2006·Granted Jun 21, 2011·15 cites·24 claims
- 0889US7776879B2Quinuclidine carbamate derivatives and their use as M3 antagonistsALMIRALL SA·Filed 2007·Granted Aug 17, 2010·12 cites·29 claims
- 0987USRE46417EQuinuclidine derivatives and their use as muscarinic M3 receptor ligandsALMIRALL SA·Filed 2016·Granted May 30, 2017·4 cites·30 claims
- 1087US9233108B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2012·Granted Jan 12, 2016·9 cites·3 claims
- 1186US10034867B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2017·Granted Jul 31, 2018·2 cites·21 claims
- 1284US7893087B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2006·Granted Feb 22, 2011·5 cites·22 claims
- 1382US9562039B2Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activitiesALMIRALL SA·Filed 2014·Granted Feb 7, 2017·10 cites·11 claims
- 1481US7879874B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2006·Granted Feb 1, 2011·3 cites·23 claims
- 1579US9757383B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Sep 12, 2017·2 cites·7 claims
- 1679US9549934B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Jan 24, 2017·2 cites·3 claims
- 1778US9254262B2Dosage and formulationALMIRALL SA·Filed 2012·Granted Feb 9, 2016·6 cites·23 claims
- 1875US10759793B22-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitorsALMIRALL SA·Filed 2016·Granted Sep 1, 2020·3 cites·13 claims
- 1975US10005771B2Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2015·Granted Jun 26, 2018·2 cites·26 claims
- 2074US9643961B2Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2016·Granted May 9, 2017·2 cites·3 claims
- 2173US10588895B2Quinuclidine derivatives and medicinal compositions containing the sameALMIRALL SA·Filed 2018·Granted Mar 17, 2020·0 cites·13 claims
- 2273US9579316B2Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activitiesALMIRALL SA·Filed 2014·Granted Feb 28, 2017·3 cites·9 claims
- 2370US9737520B2Aclidinium for use in improving the quality of sleep in respiratory patientsALMIRALL SA·Filed 2016·Granted Aug 22, 2017·4 cites·15 claims
- 2467US10085974B2Dosage and formulationALMIRALL SA·Filed 2012·Granted Oct 2, 2018·1 cites·22 claims
- 2567US9518050B2Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activityALMIRALL SA·Filed 2013·Granted Dec 13, 2016·2 cites·46 claims
- 2665US9907807B2Topical pharmaceutical compositionsALMIRALL SA·Filed 2015·Granted Mar 6, 2018·2 cites·6 claims
- 2765US8820321B2Storage system for powdered pharmaceuticals, and inhaler equipped with this systemALMIRALL SA·Filed 2012·Granted Sep 2, 2014·2 cites·4 claims
- 2865US2025381172A1Novel dosage and formulationALMIRALL SA·Filed 2025·Application pending·0 cites
- 2965US2021330628A1Pharmaceutical Compositions Comprising Dimethyl FumarateALMIRALL SA·Filed 2021·Application pending·0 cites
- 3065US2016310457A1Pharmaceutical compositions comprising dimethyl fumarateALMIRALL SA·Filed 2014·Application pending·0 cites
- 3160US10300072B2Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesALMIRALL SA·Filed 2017·Granted May 28, 2019·0 cites·24 claims
- 3260US8375940B2Storage system for powdered pharmaceuticals and inhaler equipped with this systemALMIRALL SA·Filed 2007·Granted Feb 19, 2013·1 cites·10 claims
- 3359US11000517B2Dosage and formulationALMIRALL SA·Filed 2018·Granted May 11, 2021·0 cites·29 claims
- 3459US10434268B2Inhalation device for powdered drugsALMIRALL SA·Filed 2013·Granted Oct 8, 2019·2 cites·9 claims
- 3557US9388189B2Pyrrolotriazinone derivatives as PI3K inhibitorsALMIRALL SA·Filed 2013·Granted Jul 12, 2016·1 cites·20 claims
- 3657US8051851B2Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhalerALMIRALL SA·Filed 2005·Granted Nov 8, 2011·2 cites·17 claims
- 3756US2023374158A1Bispecific molecules and methods of treatment using the sameALMIRALL SA·Filed 2021·Application pending·0 cites
- 3854US2023235040A1Anti-il-36 antibodies and methods of use thereofALMIRALL SA·Filed 2021·Application pending·0 cites
- 3953US2014343097A15-(2-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one for the treatment of lung functionALMIRALL SA·Filed 2014·Application pending·0 cites
- 4052US2014038928A15-(2--1-hydroxyethyl-8-hydroxyquinolin-2 (1h)-one and its use in the treatment of pulmonary diseasesALMIRALL SA·Filed 2013·Application pending·0 cites
- 4151US2015140099A1Novel dosage form and formulation of abediterolALMIRALL SA·Filed 2013·Application pending·0 cites
- 4246US2016303108A1Novel dosage form and formulation of abediterolALMIRALL SA·Filed 2016·Application pending·0 cites
- 4346US2014005178A1Azabiphenylaminobenzoic acid derivatives as dhodh inhibitorsALMIRALL SA·Filed 2013·Application pending·0 cites
- 4446US2020255478A1Novel compounds activating the nrf2 pathwayALMIRALL SA·Filed 2018·Application pending·0 cites
- 4545US7954492B2Pharmaceutical powder cartridge, and inhaler equipped with sameALMIRALL SA·Filed 2005·Granted Jun 7, 2011·0 cites·15 claims
- 4644US2014000602A1Inhalation device for drugs in powder formALMIRALL SA·Filed 2013·Application pending·0 cites
- 4744US2016331733A1New use of aclidiniumALMIRALL SA·Filed 2016·Application pending·0 cites
- 4844US2021220368A1Compositions comprising timolol and their use in the treatment of rosacea by topical administrationALMIRALL SA·Filed 2017·Application pending·0 cites
- 4943US2017158699A1Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrileALMIRALL SA·Filed 2015·Application pending·0 cites
- 5042US2015328194A1New use of aclidiniumALMIRALL SA·Filed 2013·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ALMIRALL SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →